Purpose: Adjuvant whole breast radiation therapy after breast-conserving surgery is the standard of care in the management of early-stage breast cancer. Two of the most common acute toxicities of breast radiation therapy are radiation esophagitis (RE) and radiation dermatitis (RD). African American individuals are at higher risk for experiencing treatment-related toxic effects and are often underrepresented in clinical trials.
Methods And Materials: An institutional database was developed to include all African American patients with a history of breast cancer or ductal carcinoma in situ undergoing adjuvant radiation therapy at a single institution from 2013 to 2019. Records were reviewed to identify patient age, body mass index (BMI), radiation dose, prone versus supine position, inclusion of boost, and inclusion of regional nodal irradiation. Radiation treatment plans were reviewed to identify breast size as well as dosimetric parameters to the breast and esophagus. Medical records were reviewed to identify which patients were prescribed Silvadene or Mylanta-lidocaine during or immediately after their course of radiation therapy, which was used as a surrogate for grade 2 (G2) or higher RD or RE, respectively.
Results: A total of 272 patients were included in the final analysis. On univariable analysis, patients with morbid obesity were more likely to develop G2RD, whereas hypofractionated radiation therapy was associated with lower rates of G2RD. On multivariable analysis, greater breast volume was associated with higher rates of G2RD. In the subset of patients receiving regional node irradiation, 19% of the patients experienced G2RE, and the best predictor on multivariable analysis was the mean radiation dose (D) to the esophagus.
Conclusions: Radiation dermatitis and esophagitis are common toxic effects in African American patients undergoing adjuvant breast radiation therapy. In this study, greater breast size, irrespective of the patient's BMI, was associated with a higher rate of dermatitis. Prone positioning during treatment and hypofractionated radiation reduced rates of G2RD. The D to the esophagus was the dosimetric parameter most correlated with G2RE. These results may be used to help select patients at higher risk for toxic effects of G2 or greater during radiation therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.prro.2021.08.004 | DOI Listing |
Combining radiotherapy with targeted therapy benefits patients with advanced epidermal growth factor receptor-mutated non-small cell lung cancer (EGFRm NSCLC). However, the optimal strategy to combine EGFR tyrosine kinase inhibitors (TKIs) with radiotherapy for maximum efficacy and minimal toxicity is still uncertain. Notably, EVs, which serve as communication mediators among tumor cells, play a crucial role in the anti-tumor immune response.
View Article and Find Full Text PDFSensors (Basel)
December 2024
Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
(1) Background: Ultra-high dose rate (UHDR) radiation therapy needs a reliable dosimetry solution and scintillation detectors are promising candidates. In this study, we characterized an inorganic powder-based scintillation detector under a 9 MeV UHDR electron beam. (2) Methods: A mixture of ZnS:Ag powder and optic glue was coupled to an 8 m Eska GH-4001-P polymethyl methacrylate (PMMA) optical fiber.
View Article and Find Full Text PDFPharmaceutics
December 2024
Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Nanodrug delivery systems have revolutionized tumor therapy like never before. By overcoming the complexity of the tumor microenvironment (TME) and bypassing drug resistance mechanisms, nanotechnology has shown great potential to improve drug efficacy and reduce toxic side effects. This review examines the impact of the TME on drug resistance and recent advances in nanomedicine delivery systems to overcome this challenge.
View Article and Find Full Text PDFPharmaceutics
December 2024
Wits Advanced Drug Delivery Platform, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, 7 York Road, Parktown, Johannesburg 2193, South Africa.
The effectiveness of paclitaxel (PTX) in treating non-small-cell lung carcinoma (NSCLC) is restricted by its poor pharmacokinetic profile and side effects. This limitation stems from the lack of a suitable delivery vector to efficiently target cancer cells. Therefore, there is a critical need to develop an efficient carrier for the optimised delivery of PTX in NSCLC therapy.
View Article and Find Full Text PDFPharmaceutics
November 2024
Department of Cell Biology and Molecular Genetics, Sri Devraj Urs Medical College, Sri Devaraj Urs Academy of Higher Education and Research, Kolar 563103, India.
Cancer, the most common condition worldwide, ranks second in terms of the number of human deaths, surpassing cardiovascular diseases. Uncontrolled cell multiplication and resistance to cell death are the traditional features of cancer. The myriad of treatment options include surgery, chemotherapy, radiotherapy, and immunotherapy to treat this disease.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!